In a significant cross-border collaboration, Australian biotech company AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have entered into an agreement with Shanghai Cell Therapy Group (SHcell) to co-develop and commercialise a cutting-edge cancer treatment, BZDS1901, outside China. …
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 Australian BiotechBioPharmaDispatch Executive
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News